The exploration of CD64 in diagnosing periprostheic joint infection

The exploration of Leucocyte Differential Antigen CD64 in diagnosing periprostheic joint infection after arthroplasty

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900025339

Enrollment

Unknown

Registered

2019-08-24

Start date

2019-08-24

Completion date

Unknown

Last updated

2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periprosthetic joint infection

Interventions

Gold Standard:MSIS(Muskuloskeletal Infection Society)2011 criteria for periprosthetic joint infection

Index test:Neutrophil&#32

membrane&#32

CD64&#32

expression

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Patients who underwent hip/knee revision surgery from July 2019 to March 2020 will be selected; 2. Aged over 18 years; 3. Joint revision due to non-infection reasons / periprosthetic infection, hip/knee revision surgery.

Exclusion criteria

Exclusion criteria: 1. tumor comorbidity; 2. immunosuppressive states; 3. infections other than periprosthetic joint infection.

Design outcomes

Primary

Measure	Time frame
Blood Neutrophil membrane CD64 expression;Synovial fluid Neutrophil membrane CD64 expression;Synovial fluid soluble CD64 concentration;SEN, SPE, ACC, AUC of ROC;	—

Secondary

Measure	Time frame
Blood CRP;Blood ESR;intraoperative pathology;Synovial fluid culture or tissue culture;sinus;Synovial fluid white blood cell count and polymorphonuclear cell percentage;	—

Countries

China

Contacts

Public ContactChen Jiying

Orthopedic Department, The First Medical Center of PLA General Hospital

jiyingchen_301@163.com+86 13901078832

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026